Current Report Filing (8-k)
March 09 2017 - 4:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report
(Date of
earliest event reported)
March 3, 2017
INOVIO
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-14888
|
|
33-0969592
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
660 W. Germantown Pike, Suite 110
Plymouth Meeting, Pennsylvania
|
|
19462
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (267) 440-4200
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On March 3, 2017, Nancy J. Wysenski, a director of the Company, informed the Board of Directors (the Board) of the Company
that she will not stand for re-election as a director of the Company at the Companys 2017 Annual Meeting of Stockholders. Accordingly, Ms. Wysenskis service on the Board will conclude effective as of the election of directors at the
2017 Annual Meeting. Ms. Wysenski informed the Board that she was declining to stand for re-election for personal reasons. The Companys Nomination and Corporate Governance Committee is in the process of identifying qualified outside
director candidates.
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
INOVIO PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Peter Kies
|
|
|
Peter Kies,
Chief Financial
Officer
|
Date: March 9, 2017
-3-
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024